Bilthoven, the Netherlands / Munich, Germany, July 6, 2022. DZNE with SyNergy member Dieter Edbauer and Intravacc B.V., a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines, have been awarded a funding of € 2.5 million from the European Union (EIC Transition Grant) to further develop a prototype ALS vaccine, including process development, scale-up and toxicology study. The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.